PRMT5 and hematopoietic and lymphoid cell neoplasm: PRT543, a potent orally available PRMT5 inhibitor [43], has demonstrated an early signal of anti-tumor activity in a subset of patients with several solid and hematological cancers, including ACC [45, 114, 115].